Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab to reduce allo-sensitization after kidney graft nephrectomy
2020-001087-28Phase 2Completed
- Sponsor
- Centre hospitalier universitaire de Toulouse
- Start
- Oct 2020
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tocilizumab in Kidney allograft failure, sponsored by Centre hospitalier universitaire de Toulouse. Primary endpoint: Occurrence of infectious complications following graft nephrectomy. Started Oct 2020; status: completed.
02
Drugs
tocilizumab
03
Conditions
Kidney allograft failure
Beyond the preview
Go deeper on 2020-001087-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2020-001087-28.